Randomized Controlled Trial of Neurokinin 3 Receptor Antagonist Fezolinetant for Treatment of Polycystic Ovary Syndrome.
Graeme L FraserBarbara Obermayer-PietschJoop LavenGeorg GriesingerAxelle PintiauxDirk TimmermanBart C J M FauserChristopher LademacherJean CombalbertHamid R HoveydaSteven RamaelPublished in: The Journal of clinical endocrinology and metabolism (2021)
Fezolinetant had a sustained effect to suppress hyperandrogenism and reduce the LH-to-FSH ratio in women with PCOS.